Hepatitis C inhibitor peptide analogs

Details Hepatitis C inhibitor peptide analogs Hepatitis C inhibitor peptide analogs

2005-06-21

2005-06-21

Tate, Christopher (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S002600

Reexamination Certificate

active

06908901

ABSTRACT:
Compounds of formula (I):wherein B, Y, R3, R24, R2, R1and RCare defined herein. The compounds are useful as inhibitors of HCV NS3 protease.

REFERENCES:
patent: 6323180 (2001-11-01), Llinas-Brunet et al.
patent: 6329379 (2001-12-01), Llinas-Brunet et al.
patent: 6410531 (2002-06-01), Llinas-Brunet et al.
patent: 6420380 (2002-07-01), Llinas-Brunet et al.
patent: 6534523 (2003-03-01), Llinas-Brunet et al.
patent: 6642204 (2003-11-01), Llinas-Brunet et al.
patent: WO 99/07733 (1999-02-01), None
patent: WO 00/09543 (2000-02-01), None
patent: WO 00/09558 (2000-02-01), None
Naps and Johns; Optically active mono-substituted sucolnic acids and derivatives; Journal of American Chemical Society, vol. 62, 1940, pp. 2450-2457.

Affiliated with

Also associated with

Rating

Hepatitis C inhibitor peptide analogs does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Hepatitis C inhibitor peptide analogs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hepatitis C inhibitor peptide analogs will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3461608